Technical Analysis for NRIX - Nurix Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Historical NRIX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 4.96% | |
| 50 DMA Resistance | Bearish | 4.96% | |
| Inside Day | Range Contraction | 4.96% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Up 5% | 2 days ago | |
| Rose Above Previous Day's High | 2 days ago | |
| Up 3% | 2 days ago | |
| 60 Minute Opening Range Breakout | 2 days ago | |
| Up 2% | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Sanofi Small Molecule Therapies Gilead Sciences Immune Disorders Bruton's Tyrosine Kinase
Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Sanofi Small Molecule Therapies Gilead Sciences Immune Disorders Bruton's Tyrosine Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.46 |
| 52 Week Low | 15.21 |
| Average Volume | 172,395 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 27.41 |
| 20-Day Moving Average | 27.28 |
| 10-Day Moving Average | 26.08 |
| Average True Range | 2.49 |
| ADX | 14.8 |
| +DI | 24.52 |
| -DI | 18.81 |
| Chandelier Exit (Long, 3 ATRs ) | 28.45 |
| Chandelier Exit (Short, 3 ATRs ) | 30.55 |
| Upper Bollinger Band | 33.15 |
| Lower Bollinger Band | 21.41 |
| Percent B (%b) | 0.59 |
| BandWidth | 43.04 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.31 |
| MACD Histogram | 0.1069 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 31.86 | ||||
| Resistance 3 (R3) | 31.61 | 30.21 | 31.28 | ||
| Resistance 2 (R2) | 30.21 | 29.32 | 30.33 | 31.09 | |
| Resistance 1 (R1) | 29.29 | 28.77 | 29.75 | 29.54 | 30.89 |
| Pivot Point | 27.89 | 27.89 | 28.12 | 28.01 | 27.89 |
| Support 1 (S1) | 26.97 | 27.00 | 27.43 | 27.22 | 25.87 |
| Support 2 (S2) | 25.57 | 26.45 | 25.69 | 25.67 | |
| Support 3 (S3) | 24.65 | 25.57 | 25.48 | ||
| Support 4 (S4) | 24.90 |
